Clinical trials

The purpose of this study is to assess the effectivemenss of durvalumab plus tremelimumab in combination with chemotherapy complated with pembrolizumab in combination with chemotherapy (pemetrexed) in participants with metastaic lung cancer containing certain mutations. 

This study will assess the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to SOC (surgical resection with/without adjuvant RT at investigator's discretion). Participants with clinical complete response, on clinical examination and by imaging and confirmed by negative biopsy, have the option not to undergo surgery, at the investigator's discretion, and will proceed to adjuvant therapy. It is a Phase 2/3 adaptive design study, and Phase 3 expansion will be determined by prespecified Go-No-Go decision.

The purpose of this study is to compare the usual treatment to using the study drugs, Relatlimab and Nivolumab. The use of the study drugs, Relatlimab and Nivolumab, could shrink or stabilize your cancer.

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant ± abemaciclib as compared to standard ET ± abemaciclib of patients with ER+/HER2- early breast cancer.

For participants who meet eligibility criteria to be screened for lung cancer, Inova is conducting a research project studying the cells of the nose and blood. Biomarkers (a substance in the airway and blood that is an indicator of a condition) have been identified for the early detection of lung cancer. The study is investigating if biomarkers can be used as an adjunct to screening CT scans.

While previously identified biomarkers have helped with lung cancer detection in patients with lung nodules (a small mass or lump), use of biomarkers in patients undergoing screening CT scans has not yet been determined. In this project, Inova will investigate if biomarkers from the nose or blood can help in the screening process for lung cancer. The biomarkers tests are experimental.
This study is being funded by a grant from Inova Health System.

Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.

As part of a multidisciplinary cancer screening program that is being conducted by the Saville Cancer Screening and Prevention Center and Department of Occupational Health within the Inova Health System, the purpose of this research study is to generate preliminary data on the clinical impact of investigational cancer screening modalities in career and volunteer firefighters.

Aims include evaluating the clinical impact and performance of cancer detection tools, the diagnostic follow-up and healthcare utilization prompted by use of each investigational tool, and assessments of anxiety and feasibility of implementation related to the screening protocols in participants. It is anticipated that results from this pilot will support the development of future firefighter cancer screening programs and serve as a research framework that can be adopted and tested within other health systems in partnership with the local fire jurisdictions in their catchment area, with the ultimate goal of identifying the risks and benefits of these tools for early cancer detection in the firefighter population.

This study receives partial funding from the Virginia Department of Health.

This is a two-arm, randomized, double blind, placebo-controlled study of Optune (Tumor Treating Fields at 200 kHz) to the brain concomitant with maintenance Temozolomide (TMZ) chemotherapy agent  and pembrolizumab compared to Optune concomitant with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

The purpose of this research study is to see if ABBV-400 has any benefits at dose levels thought to be acceptable in earlier studies. The researchers want to find out what effects (good and bad) ABBV-400 has on metastatic colorectal cancer.

The goal of this study is to determine the optimal dose level for the study drug ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab to define the recommended Phase 3 dosage regimen for the combination and to evaluate the efficacy (how well the study drug works), safety and tolerability of the study drug in patients with unresectable metastatic colorectal cancer who have received prior therapy for this colorectal cancer and have progressed during or after the prior treatment.

This study aims to assess whether a 3-week hypofractionated proton radiation therapy regimen for breast cancer, targeting the breast/chest wall and regional lymph nodes, is as effective as a traditional 5-week regimen in terms of skin and soft tissue side effects. Specifically, it seeks to determine if the shorter treatment duration results in comparable rates of both acute and late side effects when compared to the longer, conventionally fractionated proton therapy schedule.